Cargando…
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
Patient-derived autologous chimeric antigen receptor (CAR)-T cell therapy is a revolutionary breakthrough in immunotherapy and has made impressive progress in both preclinical and clinical studies. However, autologous CAR-T cells still have notable drawbacks in clinical manufacture, such as long pro...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405079/ https://www.ncbi.nlm.nih.gov/pubmed/37554322 http://dx.doi.org/10.3389/fimmu.2023.1199145 |